A PROSPECTIVE, SINGLE-CENTERED, ASSESSOR-BLINDED STUDY TO EVALUATE THE CLINICAL EFFICACY OF THE PROPOSED CELL/TISSUE HISTOPATHOLOGY PROCESSOR CCELL (CONFOCAL FLUORESCENCE ENDOMICROSCOPY) FOR INTRAOPERATIVE DIAGNOSIS IN BRAIN TUMORS

VPIX Medical

Status and phase: Not yet enrolling; Phase 1

Conditions: Frozen Sections; Brain Tumor; Indocyanine Green (ICG)

Treatments: Device: cCeLL In vivo; Drug: Indocyanine Green

Study type: Interventional

Funder types: Industry

Identifiers

NCT07254845

cCeLL_II_2025_Cedars

Details and patient eligibility

About

The primary objective of this single-center study is to demonstrate the performance of cCeLL, used in real time, compared to frozen section analysis. The investigational device is intended for use with indocyanine green (ICG) for fluorescence imaging as an aid in the visualization of vessels (micro- and macro-vasculature) blood flow in the cerebrovascular before, during or after cranial diagnostic and therapeutic procedures, such as tumor biopsy and resection, and the images will be immediately transmitted to a single pathologist for real-time evaluation, without influencing the surgical decision-making process. The comparison will be made between the device and the conventional intraoperative histological frozen section analysis of identical brain tissue samples in the same patient. Both methods will be compared in terms of their accuracy using the standard of practice, the final pathological diagnosis.

Enrollment: 30 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Male or female patients aged 18 years or older as of the screening date
2. Patients suspected of having a brain tumor who are scheduled for neurosurgery and are considered candidates for tumor resection
3. Patients who understand and have signed the informed consent form

Exclusion criteria

1. Specimens obtained from patients who have agreed to participate in this clinical trial and who meet the inclusion criteria
2. Normal tissue specimens obtained unavoidably during tumor resection surgery in tumor patients
3. Tissue samples must be adequate for both FS and PS analysis
4. Minimum lesion size of 1 cm for reliable cCeLL imaging

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

30 participants in 1 patient group

cCeLL - In vivo Imaging

Experimental group

Description:

Participants diagnosed with brain tumors will receive an intravenous injection of Indocyanine Green (ICG) during surgery. The cCeLL - In vivo confocal laser fluorescence microscope will be used to capture real-time images of the tumor margins before tissue collection. Standard frozen section and permanent section analyses will then be performed for diagnostic comparison.

Treatment:

Drug: Indocyanine Green

Device: cCeLL In vivo